4//SEC Filing
Giordano Christopher Thomas 4
Accession 0001871714-25-000002
CIK 0000034956other
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 6:38 PM ET
Size
16.7 KB
Accession
0001871714-25-000002
Insider Transaction Report
Form 4
Giordano Christopher Thomas
DirectorCEO
Transactions
- Purchase
Common Stock
2025-11-18$7.75/sh+1,612$12,500→ 1,612 total - Purchase
Common Stock
2025-11-19$7.51/sh+455$3,417→ 2,067 total - Purchase
Common Stock
2025-11-20$7.59/sh+538$4,083→ 2,605 total
Holdings
- 1,250,000
Stock Option (right to buy)
Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (1,250,000 underlying) - 157
Stock Option (right to buy)
Exercise: $3152.00Exp: 2031-07-06→ Common Stock (157 underlying) - 437
Stock Option (right to buy)
Exercise: $3.55Exp: 2034-05-17→ Common Stock (437 underlying) - 125
Stock Option (right to buy)
Exercise: $992.00Exp: 2032-06-09→ Common Stock (125 underlying) - 1,400,000
Stock Option (right to buy)
Exercise: $5.89Exp: 2035-05-16→ Common Stock (1,400,000 underlying)
Footnotes (7)
- [F1]This transaction was executed in multiple trades at prices ranging from $7.47 to $7.68. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $7.35 to $7.62. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $7.54 to $7.73. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
- [F5]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- [F6]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
- [F7]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001871714
Filing Metadata
- Form type
- 4
- Filed
- Nov 19, 7:00 PM ET
- Accepted
- Nov 20, 6:38 PM ET
- Size
- 16.7 KB